Boundless Bio Inc
BOLD
Company Profile
Business description
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
Contact
10955 Alexandria Way
Suite 100
San DiegoCA92121
USAT: +1 858 766-9912
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
64
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,741.90 | 26.70 | -0.30% |
| CAC 40 | 7,805.75 | 15.48 | 0.20% |
| DAX 40 | 24,309.16 | 14.42 | -0.06% |
| Dow JONES (US) | 42,785.74 | 466.00 | 1.10% |
| FTSE 100 | 8,831.98 | 20.94 | 0.24% |
| HKSE | 23,792.54 | 114.43 | -0.48% |
| NASDAQ | 19,557.37 | 258.92 | 1.34% |
| Nikkei 225 | 37,741.61 | 187.12 | 0.50% |
| NZX 50 Index | 12,563.48 | 13.67 | -0.11% |
| S&P 500 | 6,005.79 | 66.49 | 1.12% |
| S&P/ASX 200 | 8,515.70 | 23.20 | -0.27% |
| SSE Composite Index | 3,385.36 | 1.26 | 0.04% |